In This Section

Epigenetics in Drug Discovery

Sunday April 22, 2018

3:30 pm - 6:00 pm

Room 15B
Sponsored by the Division for Drug Discovery and Development (DDD)
Co-sponsored by the Division for Cancer Pharmacology (DCP)
Co-sponsored by the Division for Drug Metabolism and Disposition (DMDD)
Co-sponsored by Division for Toxicology (TOX)
Co-sponsored by the Division for Translational and Clinical Pharmacology (TCP)

Chair :

Joseph Jilek
University of California, Davis

Venkat Vaka
University of Mississippi Medical Center


Epigenetics is defined as the study on heritable changes in gene expression without any alterations in primary DNA sequence. Alterations in epigenetic control mechanisms lead to aberrant gene expression patterns and contribute to the pathogenesis of various diseases, including cancer, cardiovascular, and neurodegenerative diseases.The proposed symposium will introduce the topic of epigenetics and its pivotal role in drug discovery. Symposium will highlight recent advances in epigenetics research and the opportunities in leveraging epigenetic mechanisms to target-based discovery and development. Progress made in the application of the field to the development of potential therapeutics to areas beyond cancer will be discussed.

Epigenetic Drug Discovery Beyond Cancer
Patrick Woster - Medical University of South Carolina College of Pharmacy

Therapy Acceleration via Precision Medicine
Sharad Verma - Johns Hopkins School of Medicine

MicroRNA Epigenetics & Therapy: Are We Using the Right Agents?
Ai-Ming Yu - University of California, Davis

Pathway Based Chemical Screen Identifies New Components of Epigenetic Gene Repression as Potential New Cancer Therapeutics
Nate Hathaway - UNC Eshelman School of Pharmacy

Exosome Mediated Intercellular Communication in Pain
Seena Ajit - Drexel University College of Medicine

Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Kras-Induced Cell Growth and Pancreatic Cancer
Gwen Lomberk - Medical College of Wisconsin

Crosstalk Between PTBP1 and miR-101/AGO2 on Targeting MCL1  – A Novel Post-Transcriptional Mechanism for MCL1 Expression
Jia Cui - University of Alabama-Birmingham

Thank you to our Annual Meeting partners:

Amgen
University of Florida
Wake Forest University
Washington State University College of Pharmacy and Pharmaceutical Sciences
University of Wisconsin Molecular and Cellular Pharmacology Training Program
UT Health San Antonio
University of Minnesota

Emory University Pharmacology

PR & P
University of Michigan Medical School Pharmacology
jpet_banner
molpharm_banner
dmd_banner
pharmrev_banner